Allhoff T, Lenhart F P
Institut für Anaesthesiologie der Ludwig-Maximilians-Universität München.
Infusionsther Transfusionsmed. 1993 Dec;20(6):301-6.
Dextran-60 is widely used as a colloid volume substitute and for thromboprophylaxis. In order to avoid the most dangerous complication associated with dextran, the dextran-induced anaphylactic/anaphylactoid reaction (DIAR), hapten dextran is infused before starting the first application of dextran. We report of a 60-year-old man with multiple trauma, who received a dextran infusion for thromboprophylaxis because of high risk for thrombosis due to a severe thrombocytosis developing in the late postoperative period. Despite prophylaxis with monovalent hapten dextran, an anaphylactic reaction occurred. Although a serum sample drawn prior to the reaction is lacking, the causal relationship to dextran can be classified as likely, due to the close time relationship to the dextran-60 infusion. In addition, there were high titers of dextran-reactive antibodies in the blood drawn immediately after the reaction occurred. It is concluded that even after correct application of monovalent hapten dextran, dextran infusions carry the risk of severe anaphylactic reactions. They should therefore only be administered if clinical observation of the patient and the possibility of resuscitation are guaranteed.
右旋糖酐-60被广泛用作胶体容量替代品和用于血栓预防。为了避免与右旋糖酐相关的最危险并发症,即右旋糖酐诱导的过敏/类过敏反应(DIAR),在首次应用右旋糖酐之前先输注半抗原右旋糖酐。我们报告了一名60岁的多发伤男性患者,由于术后晚期出现严重血小板增多症导致血栓形成风险高,接受右旋糖酐输注以预防血栓。尽管使用单价半抗原右旋糖酐进行了预防,但仍发生了过敏反应。虽然缺乏反应前采集的血清样本,但由于与右旋糖酐-60输注的时间关系密切,与右旋糖酐的因果关系可归类为可能。此外,反应发生后立即采集的血液中存在高滴度的右旋糖酐反应性抗体。得出的结论是,即使正确应用单价半抗原右旋糖酐,右旋糖酐输注仍有发生严重过敏反应的风险。因此,只有在保证对患者进行临床观察和具备复苏可能性的情况下才能给予输注。